CN101406479A - Double-melon antihypelipidemic composition - Google Patents
Double-melon antihypelipidemic composition Download PDFInfo
- Publication number
- CN101406479A CN101406479A CNA2008101534231A CN200810153423A CN101406479A CN 101406479 A CN101406479 A CN 101406479A CN A2008101534231 A CNA2008101534231 A CN A2008101534231A CN 200810153423 A CN200810153423 A CN 200810153423A CN 101406479 A CN101406479 A CN 101406479A
- Authority
- CN
- China
- Prior art keywords
- composition
- melon
- antihypelipidemic
- double
- mass ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a biguanide hypoglycemic composition, which comprises bitter gourd polysaccharide, bitter gourd saponin and pumpkin polysaccharide based on the mass ratio of 5-15 to 0.1-5 to 5-15. The biguanide hypoglycemic composition has high content of hypoglycemic components to avoid the inconvenience of eating large amount of bitter gourds and pumpkins to reduce blood sugar by a folk method, and is easy to carry. The biguanide hypoglycemic composition is proved to have significant effect in reducing blood sugar for hyperglycemia animals through experiments on animals. The biguanide hypoglycemic composition has the advantages of clear active ingredients, specific hypoglycemic curative effect, easy testing and quality control.
Description
Technical field
The present invention relates to a kind of compound for reducing blood suger, particularly relate to a kind of double-melon antihypelipidemic composition.
Background technology
Fructus Momordicae charantiae and Fructus Cucurbitae moschatae belong to cucurbitaceous plant together.The effect that the various active composition that contains in modern pharmacology experimental study proof Fructus Momordicae charantiae and the Fructus Cucurbitae moschatae has blood sugar lowering, mutation, anti-HIV, antitumor and improves body immunity, its main activity is bitter melon polysaccharide, Fructus Momordicae charantiae saponin and squash polyoses.
Among the people, with Fructus Momordicae charantiae and Fructus Cucurbitae moschatae as diabetes patient's assistant hypoglycemic food source.But in fact to reach the purpose of blood sugar lowering by edible Fructus Momordicae charantiae and Fructus Cucurbitae moschatae, need to take in a large amount of Fructus Momordicae charantiae and Fructus Cucurbitae moschatae raw material.Because hypoglycemic activity composition bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses in Fructus Momordicae charantiae and the Fructus Cucurbitae moschatae are not high at material content, therefore, these active extraction separation need be come out, and could improve the effect of blood sugar lowering.
It is based on inositol that China Patent No. ZL03115121.3 discloses " a kind of product that contains Fructus Momordicae charantiae, Fructus Cucurbitae moschatae extract with hypoglycemic lipid-lowering effect " its main active.
Summary of the invention
The purpose of this invention is to provide a kind of definite effect, double-melon antihypelipidemic composition easy to carry.
Technical scheme of the present invention is summarized as follows:
A kind of double-melon antihypelipidemic composition is to be that the ratio of 5-15: 0.1-5: 5-15 comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin and squash polyoses in mass ratio.
Can also comprise microcrystalline Cellulose or carboxycellulose sodium, the mass ratio of the mass ratio of described microcrystalline Cellulose and described bitter melon polysaccharide or carboxycellulose sodium and described bitter melon polysaccharide is 1.8-4: 1.
The mass ratio of described bitter melon polysaccharide, Fructus Momordicae charantiae saponin and squash polyoses is preferably 10: 1: 10.
The mass ratio of the mass ratio of described microcrystalline Cellulose and described bitter melon polysaccharide or carboxycellulose sodium and described bitter melon polysaccharide is preferably 2: 1.
After a kind of double-melon antihypelipidemic composition of the present invention made tablet or capsule according to a conventional method, blood sugar lowering component content height wherein, avoid need among the people to ingest Fructus Momordicae charantiae and Fructus Cucurbitae moschatae blood sugar lowering in a large number and inconvenience that the eater is brought, and be easy to carry the blood sugar lowering determined curative effect.The prepared double-melon antihypelipidemic composition of the present invention confirms that through animal experiment hyperglycemia animal is had significant blood sugar reducing function.Product active ingredient of the present invention is clear and definite, has the advantage that is easy to detect with quality control.
The specific embodiment
The present invention is further illustrated below in conjunction with specific embodiment.
Embodiment 1
A kind of double-melon antihypelipidemic composition is that 10: 1: 10 ratio comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses in mass ratio.
Embodiment 2
A kind of double-melon antihypelipidemic composition is that 5: 1: 15 ratio comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses in mass ratio.
Embodiment 3
A kind of double-melon antihypelipidemic composition is that 10: 5: 5 ratio comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses in mass ratio.
Embodiment 4
A kind of double-melon antihypelipidemic composition is that 15: 0.1: 10 ratio comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses in mass ratio.
Embodiment 5
A kind of double-melon antihypelipidemic composition is 10: 1: 10 in mass ratio: 20 ratio comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses and microcrystalline Cellulose.
Embodiment 6
A kind of double-melon antihypelipidemic composition is 5: 1: 15 in mass ratio: 9 ratio comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses and carboxycellulose sodium, and technology is made tablet routinely.
Embodiment 7
A kind of double-melon antihypelipidemic composition is 10: 5: 5 in mass ratio: 40 ratio comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses and microcrystalline Cellulose, and technology is made capsule routinely.
Embodiment 8
A kind of double-melon antihypelipidemic composition is 15: 0.1: 10 in mass ratio: 30 ratio comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin, squash polyoses and carboxycellulose sodium, and technology is made capsule routinely.
The Fructus Momordicae charantiae saponin among embodiment 1, embodiment 4, embodiment 5 and the embodiment 6 and the extraction of bitter melon polysaccharide are pressed: ZL200510014268.1 " combined extraction method of momordica saponins and bitter melon polysaccharide " preparation.Fructus Momordicae charantiae saponin among embodiment 2, embodiment 3, embodiment 7 and the embodiment 8 and bitter melon polysaccharide are the commodity of buying, and the Fructus Momordicae charantiae saponin content among embodiment 2, embodiment 3, embodiment 7 and the embodiment 8 is similar to the content of the Fructus Momordicae charantiae saponin of ZL200510014268.1 " combined extraction method of momordica saponins and bitter melon polysaccharide " extraction.Its bitter melon polysaccharide content is similar to the content of the bitter melon polysaccharide of ZL200510014268.1 " combined extraction method of momordica saponins and bitter melon polysaccharide " extraction.
Squash polyoses among embodiment 1, embodiment 4, embodiment 5 and the embodiment 6, be to prepare: take by weighing the Fructus Cucurbitae moschatae raw material powder with following method, the pure water that adds 10 times of quality volumes, after extracting 3 hours (also can adopt 2 hours or 4 hours) under 90 ℃, centrifugal filtration, filtrate is under 50-60 ℃, during vacuum concentration to 1/5 (also 2/5), add 95% edible ethanol of 3 times of volumes, low temperature 5-10 ℃ leaves standstill 5 hours (also can be 8 hours or 10 hours), centrifugal, taking precipitate.Lyophilization promptly gets squash polyoses.
Squash polyoses among embodiment 2, embodiment 3, embodiment 7 and the embodiment 8 is the commodity of buying.
The assay method of momordica saponins: by application number is the assay method of 200510014471.9 momordica saponinss.
Animal test results:
Laboratory animal grouping and alloxan cause the foundation of rat diabetes model: 40 wistar rats are divided into 4 groups at random, if normal control group (NM), diabetes model matched group (DM) and experimental group, wherein experimental group (for the embodiment of the invention 5 preparations) is divided into 2 dosage groups, be high dose group (HM) and low dose group (LM), 10 every group.Except that NM group rat, all the other group preparation DM models.Alloxan is mixed with 2% solution with normal saline, presses the 50mg/kgBw tail vein injection behind the rat limosis 12h, for three days on end after, rat fasting 3h surveys blood glucose value, blood glucose value 〉=16.7mmol/L is that diabetes model is manufactured success, is lower than this value and discards.NM group and DM group by 10mg/kgBw every day, give distilled water, every day 1 time, totally 4 weeks through irritating stomach; High dose group (HM) and low dose group (LM) give product, every day 1 time, totally 4 weeks respectively by every day 100mg/kgBw and 26mg/kgBw through irritating stomach.
The mensuration of blood glucose: adopt glucose oxidase-peroxidase (GOD-PAP) method, operation is carried out according to the explanation of blood glucose test kit.Get blood from the rat eye socket, centrifugal 10min gets supernatant, is test serum.
Statistical analysis: adopt the SPSS11.5 statistical software to carry out statistical analysis, experimental data is represented with ± s, is relatively adopted variance analysis between group.P＜0.05 is for there being significant difference, and P＜0.01 is the difference highly significant.
(1) blood sugar detection result
A kind of double-melon antihypelipidemic composition of the present invention has certain blood sugar reducing function (table 1) to the hyperglycemic rat of model induced by alloxan.DM group rat blood sugar level and experimental group there was no significant difference before the medication, DM group rat blood sugar level is apparently higher than experimental group after the medication, HM group and LM group have relatively produced significant hypoglycemic effect with the DM group after the medication, high dose group hypoglycemic effect more obvious (p＜0.01), the HM group compares P＜0.05 with the LM group.
Table 1 product is to the influence of rat blood sugar (x ± s)
Double-melon antihypelipidemic composition usage and dosage of the present invention, per day for adults consumption 0.1-5g (optimised quantity 2g) obeys at twice, takes for a long time.
Double-melon antihypelipidemic composition of the present invention has tangible hypoglycemic effect.
Claims (4)
1. double-melon antihypelipidemic composition is characterized in that in mass ratio being that the ratio of 5-15: 0.1-5: 5-15 comprises bitter melon polysaccharide, Fructus Momordicae charantiae saponin and squash polyoses.
2. a kind of double-melon antihypelipidemic composition according to claim 1, it is characterized in that also comprising microcrystalline Cellulose or carboxycellulose sodium, the mass ratio of the mass ratio of described microcrystalline Cellulose and described bitter melon polysaccharide or carboxycellulose sodium and described bitter melon polysaccharide is 1.8-4: 1.
3. a kind of double-melon antihypelipidemic composition according to claim 1, the mass ratio that it is characterized in that described bitter melon polysaccharide, Fructus Momordicae charantiae saponin and squash polyoses is 10: 1: 10.
4. a kind of double-melon antihypelipidemic composition according to claim 2 is characterized in that the mass ratio of described microcrystalline Cellulose and described bitter melon polysaccharide or the mass ratio of carboxycellulose sodium and described bitter melon polysaccharide are 2: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101534231A CN101406479A (en) | 2008-11-26 | 2008-11-26 | Double-melon antihypelipidemic composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101534231A CN101406479A (en) | 2008-11-26 | 2008-11-26 | Double-melon antihypelipidemic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101406479A true CN101406479A (en) | 2009-04-15 |
Family
ID=40569824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101534231A Pending CN101406479A (en) | 2008-11-26 | 2008-11-26 | Double-melon antihypelipidemic composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101406479A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953875A (en) * | 2010-09-16 | 2011-01-26 | 天津农学院 | Bitter gourd extract composition for synergistically reducing blood sugar and preventing hyperglycemia |
| US20110097415A1 (en) * | 2009-10-26 | 2011-04-28 | Yaguang Liu | Sustained release of pharmaceutical composition containing a safe botanic drug for the treating and preventing of diabetes |
| CN106214623A (en) * | 2016-03-08 | 2016-12-14 | 兰州理工大学 | There is the preparation method of the squash polyoses composite aquogel of blood sugar reducing function |
-
2008
- 2008-11-26 CN CNA2008101534231A patent/CN101406479A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110097415A1 (en) * | 2009-10-26 | 2011-04-28 | Yaguang Liu | Sustained release of pharmaceutical composition containing a safe botanic drug for the treating and preventing of diabetes |
| US8114444B2 (en) * | 2009-10-26 | 2012-02-14 | Yaguang Liu | Pharmaceutical composition containing Momordica charantia L. extracts for lowering blood glucose |
| CN101953875A (en) * | 2010-09-16 | 2011-01-26 | 天津农学院 | Bitter gourd extract composition for synergistically reducing blood sugar and preventing hyperglycemia |
| CN106214623A (en) * | 2016-03-08 | 2016-12-14 | 兰州理工大学 | There is the preparation method of the squash polyoses composite aquogel of blood sugar reducing function |
| CN106214623B (en) * | 2016-03-08 | 2019-07-23 | 兰州理工大学 | The preparation method of squash polyoses composite hydrogel with blood sugar reducing function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100486596C (en) | Chinese medicine preparation with organism immunity increasing function | |
| CN101829172A (en) | Ganoderma-lucidum medicinal mycoplasm, pharmaceutical preparation, pharmaceutical composition and food composition | |
| EP1210095A1 (en) | Withania somnifera composition | |
| CN102757508A (en) | Application of ophiopogon polysaccharide extract in preparing foodstuff additives, health-care products or medicines with weight-reducing function | |
| CN104042679A (en) | Hypoglycemic product containing cyclocarya paliurus | |
| CN103156869A (en) | Sanggenone C and sanggenone D extracted from morus plants and new medicine application of composition | |
| CN101401829A (en) | Wild Jinchai liveness extract, preparation and uses thereof | |
| CN103860604A (en) | Compound tablet containing kelp extract and cordyceps militaris | |
| CN101347495B (en) | Preparation of Glabridin dispersible tablets and use of the tablets in reducing blood sugar as medicament active composition | |
| CN103961534A (en) | Method for preparing cordyceps polysaccharide biological preparation | |
| CN101406479A (en) | Double-melon antihypelipidemic composition | |
| CN107569608B (en) | Pharmaceutical composition for reducing blood sugar | |
| CN102068475B (en) | Application and blood-sugar lowering effective part of trapa acornis nakano shell as well as extraction method of blood-sugar lowering effective part | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN111700927B (en) | Medicinal and edible composition with blood sugar reducing effect and preparation method and application thereof | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN105192820A (en) | Blood-fat-reducing cordyceps militaris polysaccharide beverage and preparing method thereof | |
| CN101564511B (en) | Natural protein product for treating diabetes and manufacture method | |
| CN109662232A (en) | A kind of Rosa roxburghii Tratt ethanol extract effervescent tablet production method | |
| CN104940428B (en) | Hypoglycemic composition containing wolfberry fruits and application thereof | |
| CN108853184A (en) | A kind of blue or green money willow and Pasania cuspidata extract combination | |
| CN113243528B (en) | Corn silk extract capable of efficiently reducing blood sugar and blood fat and preparation method thereof | |
| CN103721074B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN101133827B (en) | Application of ackfruit extract in the aspect of relieving or neutralizing the effect of alcohol | |
| CN106974927A (en) | Hyperoside is used to prepare the application in prevention and treatment alcoholic liver medicine or health products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090415 |